左卡尼汀对维持性血液透析患者炎症因子、氧化应激指标及心脏功能的影响

发布时间：2018-05-08 19:05

本文选题：左卡尼汀 + 维持性血液透析　；参考：《中国药房》2017年11期

【摘要】：目的:探讨左卡尼汀对维持性血液透析患者炎症因子、氧化应激指标、心脏功能的影响。方法:选择我院2014年12月-2016年2月维持性血液透析患者120例,按照随机数字表法分为观察组和对照组,各60例。对照组患者给予维持性血液透析,透析1个月后皮下注射重组人促红素注射液3 000 IU,3次/周;观察组患者在对照组基础上于透析结束后隔日给予注射用左卡尼汀2 g,iv,qod。两组患者均连续治疗3个月。观察两组患者治疗前后炎症因子[白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、C反应蛋白(CRP)]、氧化应激指标[丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)]、心脏功能指标[心排血量(CO)、左室射血分数(LVEF)、室间隔舒张末期厚度(LVST)]水平,并记录不良反应发生情况。结果:治疗前,两组患者炎症因子、氧化应激指标和心脏功能指标比较,差异均无统计学意义(P0.05)。治疗后,观察组患者IL-6、TNF-α、CRP和MDA水平较治疗前明显降低,GSH-Px、SOD、CO和LVEF水平明显升高,且观察组上述指标改善程度明显优于对照组,差异均有统计学意义(P0.05)。两组患者治疗过程中均未见明显不良反应。结论:左卡尼汀能够有效缓解维持性血液透析患者的微炎症状态,保护心脏功能,且安全性较高。
[Abstract]:Aim: to investigate the effects of levacarnitine on inflammatory factors, oxidative stress and cardiac function in maintenance hemodialysis patients. Methods: 120 patients with maintenance hemodialysis in our hospital from December 2014 to February 2016 were randomly divided into observation group and control group with 60 cases each. The patients in the control group were given maintenance hemodialysis and subcutaneously injected with recombinant human propofol injection 3 000 IUU per week after one month of dialysis, and the patients in the observation group were given levacarnitine 2 g iv qodd on the basis of the control group on the basis of the other day after dialysis. The patients in both groups were treated continuously for 3 months. The levels of inflammatory factor (IL-6), tumor necrosis factor (TNF- 伪) and C-reactive protein (CRP), oxidative stress index (MDA), glutathione peroxidase (GSH-PxN), superoxide dismutase (SOD), cardiac function were observed before and after treatment in both groups. Left ventricular ejection fraction (LVEFV), left ventricular septal end diastolic thickness (LVST), left ventricular ejection fraction (LVEF), left ventricular ejection fraction (LVST). Adverse reactions were recorded. Results: before treatment, there was no significant difference in inflammatory factor, oxidative stress index and cardiac function index between the two groups (P 0.05). After treatment, the levels of IL-6 TNF- 伪 -CRP and MDA in the observation group were significantly lower than those before the treatment. The levels of GSH-PxxSOD- CO and LVEF in the observation group were significantly higher than those in the control group, and the improvement degree of the above indexes in the observation group was significantly better than that in the control group (P 0.05). There were no obvious adverse reactions in both groups. Conclusion: levocarnitine can effectively relieve microinflammation and protect heart function in patients with maintenance hemodialysis.
【作者单位】：沧州市中心医院肾内二科;
【分类号】：R692

【相似文献】